The Remarkable Story of Copaxone: An Approach to the Treatment of Multiple Sclerosis

by Kenneth P. Johnson

"... Dr. Kenneth P. Johnson, a highly respected scientist and world-renowned expert on multiple sclerosis, recounts the fascinating tale of the development and rise to prominence of the drug Copaxone®, one of the first agents to significantly impact the course of multiple sclerosis.” From the Foreword by Aaron Miller, MD

People with MS never know when new symptoms may appear or if improvement will follow. Virtually every therapy for any human disease had been considered and tried, without finding a useful treatment. The development of Copaxone® is among the most unique of modern drug discoveries. Not only is it the enduring legacy of brilliant and determined scientists working over decades; it is also the story of The Weizmann Institute of Science and Teva Pharmaceutical Industries Ltd., two organizations that grew and prospered in spite of a most chaotic and dangerous environment during the early years of the State of Israel.

224 pages, Paperback

First published July 20, 2010

Reviews

[Mary]

While I am not on copaxone (couldn't bear the thought of daily injections; once a week is enough thank you) I wanted to see what they have to say. I remember when I did Princeton Review for the MCATS, there was an article with questions on the practice test specifically about the MS drugs. Ironically, I didn't understand it because I was in an exacerbation and not diagnosed.

Book is interesting from the perspective of how long it takes to bring a drug to the market, but it is very....well its a marketing tool for Teva and Copaxone, mixed in with the basics of MS.